Related Experiment Video
Updated: Jan 31, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways
Zhi Lan Guo1,2, Jing Zhe Li2, Yan Yan Ma2
1College of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, China.
Background:
TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, can selectively kill cancer cells with little or no cytotoxicity toward normal human cells and is regarded as a potential relatively safe antitumor drug. However, some cancer cells are resistant to TRAIL-induced apoptosis. Thus, reagents that potentiate TRAIL-induced cytotoxicity are needed. Herein, we investigated whether shikonin, a natural compound from the root of Lithospermum erythrorhizon, can sensitize TRAIL-resistant cells to TRAIL-induced cytotoxicity.
Results:
The viability of A549 cells, which were resistant to TRAIL, was significantly decreased after treatment with TRAIL followed by shikonin. The underlying mechanisms by which shikonin sensitizes cells to TRAIL-induced cytotoxicity were also examined. Combined treatment with shikonin and TRAIL activated the caspase and JNK pathways, inhibited the STAT3 and AKT pathways, downregulated the expression of Mcl-1, Bcl-2, Bcl-xL, c-FLIP and XIAP and upregulated the expression of Bid.
Conclusions:
In conclusion, the results indicated that shikonin sensitized resistant cancer cells to TRAIL-induced cytotoxicity via the modulation of the JNK, STAT3 and AKT pathways, the downregulation of antiapoptotic proteins and the upregulation of proapoptotic proteins.
Insights
Shikonin, a natural compound, sensitizes cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy. This combination enhances TRAIL
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- TRAIL is a promising antitumor agent due to its selective cancer cell toxicity.
- Cancer cells can develop resistance to TRAIL-induced apoptosis, limiting its therapeutic efficacy.
- Novel agents are required to overcome TRAIL resistance and enhance its antitumor effects.
Purpose of the Study:
- To investigate the potential of shikonin, a natural compound, in sensitizing TRAIL-resistant cancer cells.
- To elucidate the molecular mechanisms underlying shikonin's sensitizing effects on TRAIL-induced cytotoxicity.
Main Methods:
- Treatment of TRAIL-resistant A549 cancer cells with shikonin and TRAIL.
- Analysis of cell viability and apoptosis.
- Examination of key signaling pathways (caspase, JNK, STAT3, AKT) and protein expression levels (Mcl-1, Bcl-2, Bcl-xL, c-FLIP, XIAP, Bid).
Main Results:
- Shikonin significantly decreased the viability of TRAIL-resistant A549 cells when combined with TRAIL.
- Combined treatment activated caspase and JNK pathways.
- Inhibited STAT3 and AKT pathways, downregulated antiapoptotic proteins (Mcl-1, Bcl-2, Bcl-xL, c-FLIP, XIAP), and upregulated proapoptotic Bid.
Conclusions:
- Shikonin effectively sensitizes TRAIL-resistant cancer cells to TRAIL-induced cytotoxicity.
- The sensitization mechanism involves modulation of JNK, STAT3, and AKT pathways.
- Shikonin alters the balance of pro- and antiapoptotic proteins, promoting cancer cell death.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Apoptosis
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Induced Pluripotent Stem Cells
Other Glycolytic Pathways
Auditory Pathway
When viewed cross-sectionally, the cochlea reveals the scala vestibuli and scala tympani flanking...

